title: Inhibition of stimulated Jurkat cell adenosine 3',5'-cyclic monophosphate synthesis by the immunomodulatory compound HR325.
abstract: HR325 (2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'(trifluoromethyl)-phenyl]-propenamide) is an immunomodulatory compound through pyrimidine biosynthesis inhibition with antiproliferative properties which was derived from the isoxazol compound A77 1726 [2-cyano-3-cyclopropyl-3-hydroxy-enoic acid (4-trifluoromethylphenyl)-amide]. During studies of the effects on early signal transduction events of this type of compound, it was found that HR325 dose-dependently inhibited adenosine 3',5'-cyclic monophosphate (cAMP) synthesis by Jurkat cells stimulated with prostaglandin E(2), (PGE(2)), cholera toxin (CTX), or forskolin (FKN). The potency of inhibition by HR325 of FKN-stimulated cells (IC(50) 30.4 microM) was approximately 3-fold higher than that of the other agonists (11.6 and 11.7 microM) and was independent of time of preincubation for both PGE(2) and FKN. Interestingly, A77 1726, an analogue of HR325, displayed a markedly different profile of stimulus-dependent potencies. The inhibition of cAMP synthesis by HR325 when stimulated by both PGE(2) and FKN was unaffected by glucose supplementation, in contrast to HR325-inhibited ATP levels, which were restored under such conditions. Further studies revealed that HR325 reduced intracellular ATP levels by uncoupling oxidative phosphorylation, albeit with a 1000-fold lower potency than the antihelmintic drug niclosamide. In addition, glucose supplementation experiments showed that, in contrast to HR325, the niclosamide-mediated reduction of ATP levels was wholly responsible for its inhibition of PGE(2)- and FKN-stimulated cAMP synthesis.
authors.affiliation: Immunology Domain, Hoechst Roussel, Covingham, SN3 5BZ, Swindon, UK.
authors.forename: A P
authors.initials: AP
authors.lastname: Curnock
authors.forename: T A
authors.initials: TA
authors.lastname: Thomson
authors.forename: R
authors.initials: R
authors.lastname: Westwood
authors.forename: E A
authors.initials: EA
authors.lastname: Kuo
authors.forename: R A
authors.initials: RA
authors.lastname: Williamson
authors.forename: C M
authors.initials: CM
authors.lastname: Yea
authors.forename: E
authors.initials: E
authors.lastname: Ruuthb
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000814:Aniline Compounds / Q000494:pharmacology*; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D004347:Drug Interactions; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D019169:Jurkat Cells; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D010084:Oxidation-Reduction; D010766:Phosphorylation / Q000187:drug effects
chemical_list: D000276:Adjuvants, Immunologic; D000814:Aniline Compounds; C107042:HR 325; D000255:Adenosine Triphosphate; D000242:Cyclic AMP; D005947:Glucose